Enlivex (ENLV) Net Cash Flow (2013 - 2025)
Enlivex (ENLV) posted quarterly Net Cash Flow of -$2.2 million for Q4 2025, down 506.36% year-over-year from $535000.0 in Q4 2024, and down 198.86% quarter-over-quarter from $2.2 million in Q3 2025.
Enlivex (ENLV) Net Cash Flow (2013 - 2025) Analysis & Trends
Enlivex's Net Cash Flow history runs 13 years deep, the most recent figure standing at -$2.2 million for Q4 2025.
- In Q4 2025, Net Cash Flow fell 506.36% year-over-year to -$2.2 million; the TTM figure through Dec 2025 stood at -$1.4 million (down 154.21% YoY), while the FY2025 annual figure was -$1.4 million, down 154.21% from the prior year.
- Net Cash Flow for Q4 2025 stood at -$2.2 million, down from $2.2 million in the prior quarter.
- The five-year high for Net Cash Flow was $56.5 million in Q1 2022, with the low at -$47.5 million in Q2 2022.
- The 5-year median for Net Cash Flow is -$991500.0 (2021), against an average of -$211550.0.
- The sharpest annual moves came in 2021 and 2022: Net Cash Flow tumbled 3707.25% in 2021, then soared 5673.05% in 2022.
- Enlivex's Net Cash Flow stood at -$11.9 million in 2021, then surged by 35.56% to -$7.7 million in 2022, then soared by 85.16% to -$1.1 million in 2023, then jumped by 146.85% to $535000.0 in 2024, then plunged by 506.36% to -$2.2 million in 2025.
- Business Quant data shows ENLV's Net Cash Flow at -$2.2 million in Q4 2025, $2.2 million in Q3 2025, and -$129000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | -2.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.17 Mn |
| Dec 31, 2025 | -2.17 Mn |
| Sep 30, 2025 | 2.20 Mn |
| Sep 30, 2025 | 2.20 Mn |
| Jun 30, 2025 | -129,000.00 |
| Jun 30, 2025 | -129,000.00 |
| Mar 31, 2025 | -1.25 Mn |
| Mar 31, 2025 | -1.25 Mn |
| Dec 31, 2024 | 535,000.00 |
| Dec 31, 2024 | 535,000.00 |
| Sep 30, 2024 | -970,000.00 |
| Sep 30, 2024 | -970,000.00 |
| Jun 30, 2024 | 1.83 Mn |
| Jun 30, 2024 | 1.83 Mn |
| Mar 31, 2024 | 1.11 Mn |
| Mar 31, 2024 | 1.11 Mn |
| Dec 31, 2023 | -1.14 Mn |
| Dec 31, 2023 | -1.14 Mn |
| Sep 30, 2023 | -1.49 Mn |
| Sep 30, 2023 | -1.49 Mn |